Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2021-05-12 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于举办2020年度网上业绩说明会的公告
AGM Information Classification · 95% confidence The document is a notice about hosting an online performance explanation meeting for the 2020 fiscal year. It mentions that the 2020 annual report has already been published and provides details about the upcoming online meeting for investors to understand the company's 2020 performance. The document is short (670 characters) and serves as an announcement for an event related to the annual report, not the report itself. Therefore, it fits the category of AGM Information (AGM-R), as it is about an annual general meeting or related investor meeting presentation.
2021-05-12 Chinese
关于募投项目结项并将节余募集资金永久补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding the completion of a fundraising investment project and the permanent allocation of surplus raised funds to supplement working capital. It details the fundraising background, project completion, surplus funds, board and supervisory approvals, independent director opinions, and sponsor verification. The document is structured as a formal announcement about the use and management of raised funds rather than a full financial report or audit. It does not contain comprehensive financial statements or quarterly/yearly financial results. It is not a report publication announcement since it contains substantive information about the fundraising project conclusion and fund usage. The content aligns with a Capital/Financing Update (CAP) as it concerns the management and allocation of capital raised through an IPO and subsequent project funding.
2021-04-29 Chinese
关于2020年度拟不进行利润分配的专项说明
Notice of Dividend Amount Classification · 95% confidence The document is a formal announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding the 2020 annual profit distribution plan, specifically stating that no dividends will be distributed for the year 2020. It includes details about the company's audited net profit, the board and supervisory committee's opinions, and independent directors' opinions on the profit distribution plan. The document is an announcement of a profit distribution decision to be submitted to the shareholders' meeting for approval. It does not contain full financial statements or comprehensive financial performance data, nor is it a full annual report or interim report. It is not a call transcript, audit report, or other detailed financial report. The content fits the category of a Notice of Dividend Amount or related profit distribution announcement. Therefore, the appropriate classification is Notice of Dividend Amount (DIV). The document length is under 5,000 characters and is a detailed announcement rather than a brief report publication announcement or regulatory filing. Confidence is high due to the clear focus on profit distribution and dividend policy.
2021-04-29 Chinese
2020年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2020 年度财务决算报告' which translates to '2020 Annual Financial Settlement Report'. It contains detailed financial data for the full year 2020, including revenue, net profit, cash flow, assets, liabilities, and equity comparisons with the previous year. The document includes comprehensive financial statements and analysis for the full fiscal year, which is characteristic of an Annual Report. The length is 2850 characters, which is relatively short but the content is substantive financial data, not just an announcement or certification. There is no indication that this is a mere announcement or a certification letter. Therefore, it fits the definition of an Annual Report (10-K). FY 2020
2021-04-29 Chinese
西部证券股份有限公司关于珠海赛隆药业股份有限公司首次公开发行股票募投项目结项并将节余募集资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from a securities company (West Securities) acting as a sponsor for Zhuhai Sailong Pharmaceutical Co., Ltd. It discusses the completion of the company's initial public offering (IPO) fundraising projects, the use of surplus funds, and the permanent supplementation of working capital. It includes detailed financial figures, project progress, approvals from the board, supervisory board, and independent directors, and compliance with regulatory requirements. The document is lengthy (7,683 characters) and contains substantive financial data and analysis related to the use of IPO proceeds and project completion. It is not merely an announcement or a brief summary but a comprehensive report on the fundraising project completion and fund usage. This fits the category of a Capital/Financing Update (CAP), as it provides updates on the company's fundraising activities and the use of raised capital, including regulatory compliance and approvals. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a simple announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2021-04-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Zhuhai Sailong Pharmaceutical Co., Ltd. It details the approval of various reports and proposals including the 2020 Supervisory Board Work Report, 2020 Annual Report, 2020 Financial Final Report, 2021 Q1 Report, profit distribution plan, audit firm renewal, internal control self-evaluation report, and fundraising usage reports. The document repeatedly states that the detailed reports are published separately on the official information disclosure website (巨潮资讯网) and that these resolutions need to be submitted to the shareholders' meeting for approval. The document itself does not contain the full reports or substantive financial data but is a formal announcement of the Supervisory Board's meeting resolutions. The document length is about 3155 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document is an announcement of meeting resolutions and report approvals, not the reports themselves. It fits best into the category of Regulatory Filings (RNS) as a general regulatory announcement of meeting resolutions and approvals without the full report content.
2021-04-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.